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An incidence of 15 000 new cases of primary confirmed brain
tumours is reported in the US each year. The incidence rate
increases with age up to 65, the most frequent type being glio-
blastoma multiforme (29%), meningioma (18%), anaplastic astro-
cytoma (11%) and astrocytoma (9%) and, in spite of maximal
surgical resection and aggressive adjuvant radiotherapy and/or
chemotherapy, the prognosis for these patients is poor, with a 1.8-
year mean survival from the time of diagnosis (Mahaley et al,
1989).
Intraoperative treatment of malignant brain tumours by photo-
dynamic therapy (PDT) has been investigated in several clinical
trials (Muller and Wilson, 1991, 1996; Kostron et al, 1996). This
technique involves administering a photosensitizer which, after a
suitable time interval for uptake in the tumour, is activated by local
application of light, resulting in the generation of cytotoxic photo-
products, notably singlet oxygen, 1O2 (Dougherty and Marcus,
1992; Levy, 1994; Ochsner, 1997). The light is typically delivered
either by interstitial optical fibres (Origitano and Reichman, 1993)
or via an inflatable ‘balloon’ applicator which distributes the light
uniformly throughout the resection cavity (Schmidt et al 1996;
Muller and Wilson, 1996). These trials have shown evidence of
improved survival, and multicentre Phase III prospectively
randomized clinical trials of PDT in both de novo and recurrent
astrocytic tumours using the haematoporphyrin derivative photo-
sensitizer Photofrin (QLT Phototherapeutics Inc, Vancouver, BC,
Canada) are currently in progress. However, some studies have
also reported transient or permanent worsening of neurological
function following PDT, with neurological impairment or
neurocognitive deficit in a few patients (Muller and Wilson, 1996).
Muller and Wilson (1992) also reported increased intracranial
pressure post-operatively, attributed to PDT-induced oedema in
the exposed normal brain. These clinical complications could limit
the PDT dose and hence the anti-tumour efficacy achievable. This
is particularly relevant to the use of new, second generation photo-
sensitizers. While these may have higher tumour-to-normal brain
selectivity, in addition to other advantages such as reduced skin
photosensitization, greater light penetration at the longer wave-
lengths and higher 1O2 yield, possible damage to normal brain
tissue remains a critical concern.
In a previous pre-clinical study in a rabbit model bearing
intracranially-implanted VX2 carcinoma (Lilge et al, 1996), we
investigated necrosis of normal brain and tumour to PDT mediated
by 4 different photosensitizers: Photofrin, ALA (5-aminolaevulinic
acid: a precursor in haem biosynthesis which results in the photo-
sensitizer protoporphyrin IX, PpIX), AlClPc (non-sulphonated
chloroaluminium phthalocyanine) and SnET2 (tin ethyl etiopur-
purin). With one exception, all 4 drugs produced significant gross
haemorrhagic necrosis in both tumour and normal brain tissue.
The zones of necrosis were very sharply delineated, consistent
with a ‘threshold’ model of PDT in which a minimum concentra-
tion of 1O2 is required to produce necrosis (Chen et al, 1996; Lilge
et al, 1996; Farrell et al, 1998). There was, however, considerable
variation in the PDT threshold doses and in the tissue uptake
between the photosensitizers. In general, the threshold values for
normal brain were lower than those of tumour tissue, implying that
normal brain is intrinsically more sensitive to PDT damage than
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concentration in tumour and accurate targeting of the treatment
light. The exception was with ALA-PDT in white matter, where 
no necrotic damage was observed, probably due to lack of PpIX
synthesis.
In addition to these gross necrotic effects on normal brain and
brain adjacent to tumour (BAT), Yoshida et al (1992a) have
reported histopathologic evidence of lethal injury to neurons,
extending beyond the zone of coagulative necrosis and developing
over a period of 18 h after Photofrin-PDT in a rat model. If
generally true, this would increase further the concern over PDT
damage to normal brain structures. Hence, the focus of the present
study was to investigate sub-necrotic cell damage in brain, in
particular the occurrence of apoptosis induced in vivo.
Apoptosis has not yet been demonstrated in the PDT response of
intracranial tissues. However, PDT-induced apoptosis has been
shown in vitro in carcinoma cell lines (He et al, 1994; Noodt et al,
1996) and in other tissues in vivo, as an early event occurring
within the first 24 hours after treatment (Zaidi et al, 1993). Also,
following ionizing radiation therapy of the central nervous system,
a significant proportion of patients develop late complications,
including demyelination of nerve fibres and white matter necrosis
(Wong et al, 1994; Schultheiss et al, 1995; Laperriere et al, 1997),
and animal model studies (Li et al, 1996a,b) have confirmed radia-
tion-induced apoptosis in normal brain tissues. Hence, apoptosis is
certainly a possible mechanism of cell death following injury to
normal brain. While PDT-induced necrosis usually results from
direct photochemical injury to the cells or from destruction of
tissue vasculature with subsequent ischaemic hypoxia, apoptosis is
considered a deliberate response to specific, but often indirect
stimuli (Majno and Joris, 1995; White, 1996). The response
characteristics may, therefore, be very different.
The present study represents an initial investigation of PDT-
induced apoptosis in normal brain and intracranial tumour. It is
based on applying, retrospectively, an assay for apoptosis in brain
tissues banked from our previous studies of PDT-induced necrosis
in rabbit brain/tumour (Lilge and Wilson, 1998). While this
limited the range of treatment parameters that could be investi-
gated, and in particular provided data only at 24 h post treatment, it
served to determine whether or not PDT-induced apoptosis does
occur in brain tissues and if it is photosensitizer dependent, and 
to guide future systematic prospective studies. mTHPC (meta-
tetrahydroxyphenyl chlorin) has since been added to our pre-clin-
ical necrosis studies with Photofrin, ALA, AlClPc and SnET2, and
so is also included here.
MATERIALS AND METHODS
Animal model and PDT treatments
The animal model and PDT procedures have been described in
detail previously (Lilge and Wilson, 1998). Briefly, rabbits (New
Zealand Whites, male, 2–3.5 kg) were used since the brain is large
enough to grow tumours 8–12 mm in diameter without acute
morbidity, which facilitates determination of the PDT threshold
dose. No glial tumour is available for the rabbit, so a VX2 carci-
noma was chosen. This exhibits some relevant characteristics of
primary brain tumours, such as microinvasion, pseudo-palisading,
and growth along blood vessels and in perivascular spaces, and
causes breakdown of the blood–brain barrier (BBB) within the
tumour and in brain adjacent to tumour (BAT).
Animals were randomized for tumour implantation, photosensi-
tizer type and dose, and time interval before irradiation. Controls
were either drug/no light or light/no drug. From the set of post-
treatment brain sections obtained in our previous necrosis study
(Lilge and Wilson, 1998), a subset was selected for evaluation of
apoptosis, as listed in Table 1, which also includes the additional
animals treated using mTHPC. PDT was performed on the left
hemisphere (see below), and the contralateral hemisphere served
as a control in each animal to test for apoptosis due to photosensi-
tizer alone or for secondary whole-brain effects (e.g. due to raised
intracranial pressure). For tumour implantation, a burr hole was
drilled 5 mm posterior to the sagittal suture and 5 mm left of the
midline, through which 105 VX2 cells in 50 µ l phosphate buffered
saline (PBS) were injected 6 mm below the dura. A 13-day growth
period yielded 8–12 mm diameter tumours.
Photofrin (profimer sodium) was supplied as a freeze-dried
powder (QLT Phototherapeutics, Vancouver, BC, Canada) and
reconstituted to 5 mg/ml in 5% dextrose. ALA in hydrochloride
form (Sigma Scientific, St. Louis, MO, USA) was dissolved in
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Table 1 Summary of PDT treatment groups
Treatment Photosensitizer Light Injected Drug-light No. of No. of animals
group delivered dose time interval animals normal
energy, (mg kg–1) (h) tumour-
wavelength bearing
(J, nm)
1 Photofrin 50,514 2.5 24 3
2 Photofrin 50,514 10 24 3 1
3 ALA/PpIX 50,514 20 6 3 1
4 ALA/PpIX 50,514 100 6 3 1
5 AlCIPc 50,514 0.2–0.5 24 4 1
6 mTHPC 50,514 0.3 24 3
7 SnET2(liposome) 50,514 1.0 24 2
8 SnET2 (emulsion) 50,51A,660 1.0 24 2 1
Control
groups
I Photofrin 0,- 2.5 2
II AlCIPc 0,- 0.2 n/a 1
III None 50,514 0 1PBS (80 g/ml) and the pH was adjusted to 6.5–6.8 with 1N NaOH:
this value was selected rather than neutral or slightly basic pH in
order to keep the injectate volume as low as possible. AlClPc was
supplied in an emulsion carrier (1 mg/ml) by Dr Nancy Oleinick
(Case Western Reserve University, Cleveland, OH, USA). SnET2
(Purlytin; Miravant, Santa Barbara, CA, USA) was supplied ready
for injection in 2 different delivery vehicles: emulsion (SnET2-e)
at 1 mg/ml and liposomes (SnET2-l) at 0.87 mg/ml. mTHPC
(Scotia Drug Discovery, London, UK) was reconstituted to 0.5
mg/ml in 30% polyethylene glycol, 20% ethanol and 50% distilled
water (Scotia Pharma Ltd, London, UK). All photosensitizers
were injected intravenously at <1 ml/min, either 24 h or (for ALA)
6 h before light irradiation.
For light application, a left parietal craniotomy (12 × 8 mm) was
performed and the dura removed. Light (50 J at 35 mW) from an
argon laser (Ion-Laser Technologies, Salt Lake City, UT, USA)
was delivered via a cleaved-end optical fibre to a depth of 6 mm
into the centre of the tumour or at the same anatomical site in non-
tumour bearing animals. A wavelength of 514 nm was used to
limit the light penetration and hence the size of the PDT-induced
lesions, while achieving adequate drug activation. Two animals
given SnET2-e were irradiated at the absorption maximum of the
drug (660 nm) in order to assess the effect of the larger treatment
volume. Following treatment, the animals were allowed to recover
and analgesic (0.2 ml Temgesic, Reckitt-Colman, Hull, UK) was
then administered subcutaneously every 8 h. The animals were
sacrificed 24 h or (for SnET2) 72 h post treatment by lethal injec-
tion (T-61: Hoechst, Regina, SK, Canada), by which time necrosis
was fully developed (Yoshida et al, 1992b; Lilge and Wilson,
1998).
The brains were removed intact, fixed in 10% formalin in PBS
for 10 days, and cut into 3 mm thick transverse slices. The slice
displaying the largest diameter of necrosis was processed and
embedded in paraffin and serial 4–6 µ m sections were cut. The
TUNEL assay (Promega, Madison, WI, USA) for apoptosis was
applied to these sections, comprising terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick-end labelling, and staining
with fluorescein-12-dUTP® to identify exposed 3′ ends in the
DNA of apoptotic cells by the green fluorescein fluorescence.
Sections were counter-stained with propidium iodide (1 µ g/ml in
PBS–CaCl2, MgCl2: Molecular Probes, Eugene, OR, USA), which
stained all nucleated cells with red fluorescence. Finally, the
sections were treated with SlowFade™-Light Antifade (Molecular
Probes, Eugene, OR, USA) cover medium. Positive controls were
made during each staining session by applying 100 µ l of DNase I
(GibcoBRL, Burlington, ON, Canada) to a randomly-selected
section prior to treatment with TdT, resulting in chromosomal
fragmentation and exposure of multiple 3′ ends of DNA. Negative
controls were created by incubation of sections with a buffer
containing fluorescein-12-dUTP®, but no TdT. Randomly
selected sections representing all treatment groups were stained
during each session to minimize the impact of uncontrolled varia-
tions in staining.
A fluorescence confocal laser-scanning microscope (CLSM:
BioRad MRC 600, Mississauga, ON, Canada) was used to map the
spatial distribution and density of apoptotic bodies. These were
identified using shareware imaging software (Confocal Assistant
Version 4.02) to generate false-colour images, encoding propidium
iodide and fluorescein as red and green, respectively. The fluores-
cence excitation wavelength for propidium iodide was 564 nm,
with detection at >600 nm: fluorescein was excited at 488 nm with
detection at 535 ± 25 nm. Red blood cells (RBC) showed false-
positive green fluorescein staining which could not be distin-
guished automatically from apoptotic cells. Hence, sections were
scanned by eye to identify the latter on the basis of size and
morphology (condensed chromatin within the cytoplasm and lack
of biconcave shape). Using 600–1000  × magnification, 2 or 3
complete cross-sections from each brain were scanned by moving
the microscope stage in X and Y in 1 mm increments. The apop-
totic bodies were counted in each field-of-view, yielding a 2D
distribution of the apoptotic cells. The actual position of the treat-
ment fibre tip (centre of the light field) could not be visualized in
the sections. Hence, the geometric centre of the measured apop-
totic cell distribution was determined from the X and Y distribu-
tions, assuming that the geometric centre represents the position of
the treatment fibre tip. The radial distribution of apoptotic cell
density, D(r), (no. bodies per mm2) was thereby calculated for each
section. These were then averaged over all sections for each
animal and then for all animals in each treatment group. From light
diffusion theory, the light fluence dependence on radial distance
from a point source is of the form H(r) ∞ e–µ eff/r, where µ eff is the
effective optical attenuation coefficient of the tissue at the treat-
ment wavelength. Hence, plots of ln{r.D(r)} versus r were
compared with the corresponding radial light fluence distribution,
as measured previously (Lilge and Wilson, 1998).
In order to confirm, qualitatively, the occurrence and distribu-
tion of apoptosis, selected tissue sections directly adjacent to those
used for the TUNEL assay were H&E stained and examined under
a light microscope for cell shrinkage, karryorhexis, and pyknosis,
all of which are associated with apoptotic cell response
(Darzynkiewics et al, 1994).
RESULTS
Figure 1 shows typical examples of CLSM images with the
TUNEL assay, demonstrating positive fluorescein against the
background of propidium iodide-stained cells. Light microscopy
of H&E-stained sections exemplifies, as in Figures 2 and 3, the
apoptotic characteristics of cell shrinkage, chromosomal fragmen-
tation, and darkly-staining chromatin abutting nuclear envelopes.
The validity of the TUNEL assay applied to these brain sections
was tested using the positive and negative control slides.
Approximately 70% of the DNase-treated cells in the former
demonstrated green fluorescence, verifying the TdT labelling of
the exposed 3′ ends of DNA. None of the negative controls
showed green fluorescence, indicating that the incorporation of
Fluorescein-12-dUTP® was mediated by TdT. There was also
good correspondence between the H&E and TUNEL identification
of apoptotic cells for all treatment groups, although the former was
not quantified.
The PDT-treatment control groups (I–III) with photosensitizer or
light alone showed minimal apoptosis, with an average of 3.7 apop-
totic cells for the whole brain sections. The contralateral hemi-
spheres in all animals in treatment groups 1–7 also demonstrated
only 2–3 apoptotic cells on average, and this was supported by the
corresponding H&E-stained sections, that showed neither necrosis
nor cells with apoptotic features. Hence, there was no evidence of a
‘global’ brain response in this model with any photosensitizer when
the treatment volume was limited by the use of short wavelength
(514 nm) light. However, in group 8 treated with SnET2-e and
1112 L Lilge et al
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the contralateral hemisphere. This is most likely due to the larger
effective treatment volume.
Table 2 shows the total number of apoptotic cells observed 
in the treated hemispheres for each animal, together with the
treatment-group averages. Note that there is considerable animal-
to-animal variability in these data. In part, this appears to be due 
to the presence of ‘outliers’. For example, in Group 2 one animal
had much lower counts than the other 7 Photofrin-PDT animals.
Similarly, in Group 8 the animal treated at 514 nm had few apop-
totic bodies compared to the 2 animals treated at 660 nm, although
in this case the difference could reflect a true biological effect.
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Figure 1 Confocal fluorescence images of fluorescein-stained apoptotic
cells (bright green) in brain sections of tumour-bearing animals (1000× ). The
red cells are propidium iodide-stained. (A) 1 mg/kg SnET2-e, 50 J at 660 nm.
(B) 2.5 mg/kg Photofrin, 50 J at 514 nm
A
B
Figure 2 H&E-stained micrographs of tumour-bearing brain sections
treated with 50 J at 514 nm (1000× ). (A) 20 mg/kg ALA, sacrificed 24 h post
PDT. (B) 1 mg/kg SnET2-l, sacrificed 72 h post PDT. Both sections exhibit
condensed chromatin packed in smooth masses against the cell membrane
(arrows)
Table 2 Total number of apoptotic cells in the treated hemispheres of individual animals, and treatment group averages
Group 1 2 3 4 5 6 7 8
photosensitizer Photofrin Photofrin ALA-PplX ALA-PplX AlClPc mTHPC SnET2-l SnET2-e
PS dose 2.5 10 20 100 0.5 5 0.25–1.0 1.0
(mg kg–1)
93 59 3 17 0 20a 29 1
41 4 15 17 0 17a 29 5 b
39 83 14 6 1 12a 263b
34a 61a 49a 5a 4a 10a
Average 52 ± 28 52 ± 34 20 ± 20 11 ± 72   ± 2 15 ± 5 16 + 19/– 16 179h
Drug dose 52 ± 29 16 ± 15
average
a Non-tumour bearing animal; btreated at 660 nmPhotofrin-PDT produced the highest average count of 52 ± 29 per
whole hemisphere section. ALA-PpIX, mTHPC, and SnET2-1
produced intermediate levels of 16 ± 15, 15 ± 5, and 16 + 19/–16,
respectively, while AlClPc gave counts comparable to controls.
Direct comparisons of these values should be made with caution,
however, since they have not been corrected for differences in 
drug concentration, which vary by at least an order of magnitude
between photosensitizers (Lilge and Wilson, 1998), nor for their
different optical extinction coefficients.
In most brain sections, the apoptotic cells were localized
primarily near the region of PDT-induced necrosis or in small
pockets of viable cells within the necrotic zone. Figure 4 shows the
radial distributions of apoptotic cells for treatment groups 1–4 and
6, averaged over all animals treated using the same parameters.
The corresponding graphs for treatment groups 5 and 7 are not
shown due to the low counts, while group 8 is not shown since the
distribution was very diffuse. The radius of PDT-induced necrosis
in normal brain, as measured previously in these treatment 
groups (Lilge and Wilson, 1998) is also indicated on these graphs:
3.7 ± 0.4, 3.8 ± 0.4, >2.5, 3.1, 2.8 ± 0.4 mm for groups 2–6,
respectively. It can be seen that apoptosis occurs even beyond the
(sharp) boundary of frank necrosis in all these groups.
Figure 4 also shows the previously-determined radial distribu-
tion of light fluence in the tissue. In the case of Photofrin and
mTHPC (Figures 4A,C) the slopes of the apoptotic cell density
distribution are comparable to that of the light fluence, with
ln{r.D(r)} having an approximately linear decrease with r.
Regression fits of the radial density distributions yielded equiva-
lent effective attenuation coefficients of 0.72–0.78 mm–1, compa-
rable to the value of 0.8 ± 0.3 mm–1 measured directly (Lilge et al,
1996). The correlation coefficients were highest for Photofrin-
PDT (R2 > 0.85). Although the correlation was weakest for ALA-
PDT (0.87 > R2 > 0.69), there was still a clear decrease in
apoptosis with distance from the light source (Figure 4B). No
evidence of apoptotic cells was noted within the white matter for
ALA-PDT, while apoptotic cells were observed in this compart-
ment for animals treated with Photofrin, mTHPC and SnET2-l.
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Figure 3 H&E-stained micrographs of tumour-bearing brain sections
treated with 50 J at 514 nm (1000× ). (A) 10 mg/kg Photofrin, sacrificed 24 h
post PDT. (B) 1 mg/kg SnET2-l, sacrificed 72 h post PDT. Both sections
exhibit sickle-shaped pyknotic chromatin packed in smooth masses against
the nuclear envelope (arrows). Eosin-stained red blood cells are present





























































Figure 4 Semilog plot of r times apoptotic cell density (mm–2) vs radius
(mm) for (A) Photofrin; (B) ALA-PpIX; (C) mTHPC. Open symbols: low drug
dose. Solid symbols: high drug dose (Table 1). Squares: tumour-bearing
animals. Triangles: averages for all animals treated using the same
parameters. Vertical lines: radius of necrosis for low (dashed) and high
(solid) drug doses (Lilge and Wilson, 1998). Bold sloped line: light fluence
rate (normalized to power delivered at the fibre tip) (Lilge et al., 1996)DISCUSSION
Apoptosis is not a synchronous process (Majno and Joris, 1995),
so that cells at different stages of apoptotic death will coexist in the
same tissue section. The in situ assay employed here can detect
only the intermediate stages – DNA fragmentation, chromatin
condensation and formation of apoptotic bodies – but not the early
or late stages, such as loss of membrane asymmetry and phago-
cytosis. Hence, our measurements will underestimate the total
number of cells that undergo apoptosis in response to PDT
damage. Furthermore, the use of the previously-banked tissues
from animals sacrificed at a late time point after treatment (to
allow full development of necrosis) has not provided information
on the time course of apoptosis, nor identification of the cell types
involved. Clearly, these are important issue in terms of assessing
the true significance of PDT-induced apoptosis in the brain.
Although we have not distinguished between tumour and normal
cells scoring apoptosis, there were no statistically-significant
differences between the total counts in tumour-bearing and non-
tumour bearing animals at the 24 h time point. This is consistent
with previous findings for necrosis (Lilge and Wilson, 1998)
where, with the exception of the absence of necrosis in white
matter with ALA-PDT, the threshold dose values for a given
photosensitizer were of the same order of magnitude for both
tumour and normal brain tissue. It is noteworthy that apoptosis
also was not seen in white matter for ALA-PDT.
The control animals treated with light or photosensitizer alone,
and the contralateral hemispheres in PDT-treated animals where
the volume of PDT-induced necrosis was restricted (groups 1–7),
showed background levels of apoptosis. Thus, it is reasonably
certain that the apoptosis seen in the treated tissue is attributable to
the local photodynamic effect, whether direct cell killing or
secondary local microvascular damage.
The total apopotic counts and the volumes of PDT-induced
necrosis (Lilge and Wilson, 1998) show the same qualitative
trends in some cases: for example, the volumes of necrosis corre-
sponding to the data in Table 2 were ~195, 125 and 22 mm3 for
Photofrin, ALA (tumour or grey matter) and SnET2-1, respec-
tively. By contrast, AlClPc does not appear to produce any signifi-
cant level of apoptosis at 24 h post treatment, even although
significant necrosis was seen (~65 mm3). Chan et al (1996) and
Margaron et al (1996) have shown that phthalocyanines localize
differently in cells in vitro than either Photofrin or ALA-PpIX.
Since 1O2, which is generated by all these photosensitizers, is very
short-lived and thus acts within <~0.1 µ m of its site of generation
(Tyrrell, 1999), the intracellular sites of PDT damage will be
different for AlClPc and so might not activate the apoptotic path-
ways. This lack of consistent correlation between necrosis and
apoptosis suggests that the latter is not simply a secondary
response to the presence of necrotic tissue.
The apoptotic counts were also not dependent on the drug dose
for any of the photosensitizers, at least within the range of doses
used here, suggesting that apoptosis does not occur exclusively
from direct PDT cellular damage, but is at least partly a conse-
quence of secondary effects, such as microvascular damage, brain
swelling or hypoxia. The presence of apoptotic cells at this rela-
tively long time after treatment also supports this interpretation,
since PDT-induced apoptosis in vitro is typically complete within
a few hours (Oleinick and Evans, 1998; Separovic et al, 1998). It is
known that there is a large vascular component in the necrotic
response of normal brain tissue (Dereski et al, 1991) and
intracranial 9L glioma (Chopp et al, 1996) to Photofrin-PDT,
whereas in other tumour models aluminium phthalocyanine oper-
ates predominantly by direct cell kill (Peng et al, 1990). This is
consistent with the much larger apoptotic counts seen here with
Photofrin than with phthalocyanine, if secondary effects are indeed
important in the apoptotic response of brain tissue.
The rabbits treated with SnET2-e at 660 nm demonstrated the
largest apoptotic response of all treatment groups. However, this
was not localized to the region of necrosis or the treated hemi-
sphere. On the basis of the optical penetration depth in brain tissue
(Eggert and Blazek, 1993; Lilge and Wilson, 1998), the effective
treatment volume is ~8-fold larger at 660 nm than at 514 nm (but
still confined to the treatment hemisphere). This could cause
increased intracranial pressure and, hence, apoptosis may be a
result of secondary damage.
The form of the spatial distribution of apoptotic cells in the
tissue was quite variable (sometimes centrally-peaked and in other
cases more torroidal in shape), so that the method of determining
the geometric centre of the distribution was necessarily somewhat
arbitrary and may not coincide exactly with the location of the
treatment light source. Nevertheless, the strong correlation for
some photosensitizers between the fluence distribution and the
radial apoptotic cell density (Figure 4) suggests that the measure-
ments are not markedly skewed. These data also demonstrate that,
for these treatment parameters and time post treatment, the local
rate of PDT-induced apoptosis is proportional to the local light
fluence (and/or fluence rate, since the delivered light power was
not varied here). This is a necessary, but not sufficient, condition
for PDT-induced apoptosis also to have a threshold behaviour. The
threshold doses would then be lower than those for necrosis, since
apoptosis is seen beyond the necrotic boundary. We have recently
confirmed this quantitatively for Photofrin-PDT (Lilge et al,
2000), the threshold doses for apoptosis and necrosis in normal rat
brain being estimated as 0.6–2.7.1017 photons cm–3 and 2.2.1018
photons cm–3, respectively (minimum number of photons absorbed
by the photosensitizer per unit tissue volume to produce the
specific biological endpoint).
The predominant brain lesion seen following PDT with 514 nm
light is coagulative necrosis, since there are relatively few apop-
totic cells beyond the necrotic boundary: e.g. for Photofrin-PDT
~8,000 apoptotic cells would be present outside the necrotic
boundary according to the measurements from groups 1 and 2.
This might be interpreted to mean that apoptosis is not a major
contributor to damage to BAT and, therefore, will not be clinically
significant. However, the effect may be much greater at earlier
times. By analogy, in the case of ionizing radiation, Li et al.
(1996b) reported apoptosis in rat spinal cord peaking at 8 h,
returning to baseline levels after 24 h and, based on in vitro results
(He et al, 1994; Noodt et al, 1996) apoptosis due to direct cellular
effects of PDT is likely to occur on an even shorter time scale.
CONCLUSIONS
This study demonstrates that intracranial PDT in vivo can produce
measurable apoptosis 24 h post treatment. Furthermore, the apop-
tosis can extend beyond the boundary of frank necrosis, while the
number of apoptotic cells depends on the photosensitizer used.
However, it does not appear to depend on the photosensitizer dose,
within the ranges used. At the same time, for Photofrin, mTHPC
and, to a lesser extent, ALA-PpIX, the apoptotic cell density and
light fluence distributions correlate, demonstrating a strong local
PDT-induced apoptosis in brain tissue 1115
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tory observations will require detailed examination of the roles of
direct cell killing versus indirect, e.g. vascular, effects in brain
tissue.
The extension of apoptosis beyond the boundary of necrosis has
potentially important clinical implications, since it may increase the
extent of normal brain damage beyond the intended treatment depth,
with consequent increase in neurological risk. Conversely, since
apoptosis is not accompanied by the inflammatory response charac-
teristic of necrosis (White, 1996), selective PDT induction of local-
ized apoptosis in brain tumours could be preferable to a necrotic
response. Hence, there could also be an opportunity for improved
clinical results if PDT-induced apoptosis can be exploited.
A critical issue for future pre-clinical studies will be to deter-
mine the time course of PDT-induced apoptosis post treatment for
the different photosensitizers and treatment conditions, in order to
assess the maximum level of apoptosis that occurs beyond the
necrotic zone. This work is in progress. It is also important for
optimizing PDT dosimetry and clarifying the mechanisms of
action to confirm that apoptosis does follow a threshold model of
PDT response. A systematic drug dose, light dose and drug-light
time interval study with each photosensitizer is required in order to
quantify the relative contributions of apoptosis and necrosis to the
tissue response for different treatment parameters. For example,
recent preliminary data (Lilge et al, 2000) show much more apop-
tosis in normal brain with Photofrin-PDT at very low light doses
(1 J cm–2) that do not cause necrosis than with doses (17 J cm–2)
which do induce necrosis. Hence, it is not possible simply to
extrapolate data from high to low doses, since apoptosis and
necrosis are competing, or possibly even antagonistic, responses.
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